Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Phase 3
Completed
NCT03409614
| Condition | Non-small Cell Lung Cancer |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Regeneron Pharmaceuticals |
|---|
| Status | Completed |
|---|
| Enrollment | 789 participants |
|---|
| Interventions | REGN2810, REGN2810/chemo/ipi, Chemotherapy |
|---|
| Start date | Mar 6, 2018 |
|---|
| Completion date | Feb 27, 2025 |
|---|
| Results posted | Apr 29, 2026 |
|---|
Summary
The primary objectives of this study are: Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with advanced squamous or nonsquamous non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 in \<50% of tumor cells. Part 2: To compare the OS of cemiplimab/chemo-f with placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression. The key secondary objectives are: Part 1: To compare the progression-free survival (PFS) and objective response rate (ORR) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC and tumors expressing PD-L1 in \<50% of tumor cells. Part 2: To compare the PFS and ORR of cemiplimab/chemo-f versus placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression.
Part 1: Overall Survival (OS)
Up to a maximum of 82.2 months · months
| Part 1: Cemiplimab + Chemotherapy | 15.9 months |
|---|
| Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | 20.1 months |
|---|
| Part 1: Chemotherapy | 13.9 months |
|---|
| p-value | 0.1782 |
|---|
| Hazard Ratio (HR) | 0.813 (95% CI 0.601–1.100) |
|---|
Part 2: OS
Up to a maximum of 68.4 months · months
| Part 2: Cemiplimab + Chemotherapy | 21.1 months |
|---|
| Part 2: Placebo + Chemotherapy | 12.9 months |
|---|
| p-value | 0.0002 |
|---|
| Hazard Ratio (HR) | 0.662 (95% CI 0.531–0.825) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.